A comparative study of the benefits of monotherapy rosiglitazone versus rosiglitazone with insulin in streptozotocin-induced diabetes in rats

Ramesh Prabhu; Deepak Shankarappa; Senthil G; Venkata Naveen Kumar P; Jai Kumar

doi:10.5455/njppp.2023.13.03114202309082023

2025, Vol: 15, Issue: 2

15 / 2Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form

« Previous Article

Original Research
Online Published: 19 Aug 2023

Natl J Physiol Pharm Pharmacol. 2024; 14(3): 450-454

doi: 10.5455/njppp.2023.13.03114202309082023

A comparative study of the benefits of monotherapy rosiglitazone versus rosiglitazone with insulin in streptozotocin-induced diabetes in rats

Ramesh Prabhu, Deepak Shankarappa, Senthil G, Venkata Naveen Kumar P, Jai Kumar.

Abstract
Background: Diabetes is often associated with dyslipidemia, where plasma lipid and lipoprotein profile alterations increase the risk of coronary heart disease. Insulin resistance increases the risk of hyperinsulin and atherosclerosis, developing hypertension and diabetes. Patients with diabetes suffer from metabolic disorders in carbohydrates, fat, and proteins associated with hyperglycemia. Hence reducing insulin resistance is a therapeutic approach to treating diabetes.

Aims and Objectives: The aim of the study was to evaluate the beneficial effects of monotherapy rosiglitazone, gemfibrozil, and insulin versus rosiglitazone, gemfibrozil, and insulin combination in streptozotocin-induced diabetes in rats.

Materials and Methods: 42-Wistar rats of either sex were used in this study, except for the control group, streptozocin was used to induce diabetes. These rats were further allocated into five groups, each group consists of eight animals. Blood serum was used to estimate blood glucose and serum lipid levels were observed after a period of 6 weeks. Results were analyzed using SPSS software version 21.0.

Results: Combination therapy of insulin + rosiglitazone + gemfibrozil showed a significant decrease in serum blood glucose, lipid levels in compared with vehicle and rosiglitazone groups.

Conclusion: The results of our study demonstrated a more favorable lipid profile than the monotherapy regimen; adding gemfibrozil and insulin to rosiglitazone could help reverse the cardiovascular adverse events it causes.

Key words: Type 2 Diabetes Mellitus; Rosiglitazone; Gemfibrozil; Insulin

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Ramesh Prabhu Articles by Deepak Shankarappa Articles by Senthil G Articles by Venkata Naveen Kumar P Articles by Jai Kumar
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Prabhu R, Shankarappa D, G S, P VNK, Kumar J. A comparative study of the benefits of monotherapy rosiglitazone versus rosiglitazone with insulin in streptozotocin-induced diabetes in rats. Natl J Physiol Pharm Pharmacol. 2024; 14(3): 450-454. doi:10.5455/njppp.2023.13.03114202309082023

Web Style

Prabhu R, Shankarappa D, G S, P VNK, Kumar J. A comparative study of the benefits of monotherapy rosiglitazone versus rosiglitazone with insulin in streptozotocin-induced diabetes in rats. https://www.njppp.com/?mno=145008 [Access: March 10, 2025]. doi:10.5455/njppp.2023.13.03114202309082023

AMA (American Medical Association) Style

Prabhu R, Shankarappa D, G S, P VNK, Kumar J. A comparative study of the benefits of monotherapy rosiglitazone versus rosiglitazone with insulin in streptozotocin-induced diabetes in rats. Natl J Physiol Pharm Pharmacol. 2024; 14(3): 450-454. doi:10.5455/njppp.2023.13.03114202309082023

Vancouver/ICMJE Style

Prabhu R, Shankarappa D, G S, P VNK, Kumar J. A comparative study of the benefits of monotherapy rosiglitazone versus rosiglitazone with insulin in streptozotocin-induced diabetes in rats. Natl J Physiol Pharm Pharmacol. (2024), [cited March 10, 2025]; 14(3): 450-454. doi:10.5455/njppp.2023.13.03114202309082023

Harvard Style

Prabhu, R., Shankarappa, . D., G, . S., P, . V. N. K. & Kumar, . J. (2024) A comparative study of the benefits of monotherapy rosiglitazone versus rosiglitazone with insulin in streptozotocin-induced diabetes in rats. Natl J Physiol Pharm Pharmacol, 14 (3), 450-454. doi:10.5455/njppp.2023.13.03114202309082023

Turabian Style

Prabhu, Ramesh, Deepak Shankarappa, Senthil G, Venkata Naveen Kumar P, and Jai Kumar. 2024. A comparative study of the benefits of monotherapy rosiglitazone versus rosiglitazone with insulin in streptozotocin-induced diabetes in rats. National Journal of Physiology, Pharmacy and Pharmacology, 14 (3), 450-454. doi:10.5455/njppp.2023.13.03114202309082023

Chicago Style

Prabhu, Ramesh, Deepak Shankarappa, Senthil G, Venkata Naveen Kumar P, and Jai Kumar. "A comparative study of the benefits of monotherapy rosiglitazone versus rosiglitazone with insulin in streptozotocin-induced diabetes in rats." National Journal of Physiology, Pharmacy and Pharmacology 14 (2024), 450-454. doi:10.5455/njppp.2023.13.03114202309082023

MLA (The Modern Language Association) Style

Prabhu, Ramesh, Deepak Shankarappa, Senthil G, Venkata Naveen Kumar P, and Jai Kumar. "A comparative study of the benefits of monotherapy rosiglitazone versus rosiglitazone with insulin in streptozotocin-induced diabetes in rats." National Journal of Physiology, Pharmacy and Pharmacology 14.3 (2024), 450-454. Print. doi:10.5455/njppp.2023.13.03114202309082023

APA (American Psychological Association) Style

Prabhu, R., Shankarappa, . D., G, . S., P, . V. N. K. & Kumar, . J. (2024) A comparative study of the benefits of monotherapy rosiglitazone versus rosiglitazone with insulin in streptozotocin-induced diabetes in rats. National Journal of Physiology, Pharmacy and Pharmacology, 14 (3), 450-454. doi:10.5455/njppp.2023.13.03114202309082023

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article